Laurus Labs Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 30 Apr 2026

Company page: Laurus Labs share price, financials & guidance record

Laurus Labs reported strong Q4 and FY26 results, driven by robust growth in its CDMO business and healthy performance in Affordable Medicines. The company achieved significant margin expansion and improved capital efficiency, while strategically investing in capacity expansion and new modalities. Management expressed confidence in future growth and margin sustainability, despite acknowledging potential geopolitical and supply chain challenges.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue down 4.2%, net profit down 23.8% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	1,185	1,265	1,650	1,433	1,567 +32%	1,509 +19%	1,580 −4%
Expenses	1,003	1,059	1,255	1,105	1,177	1,164	1,205
EBITDA	182	206	395	327	390 +114%	346 +68%	375 −5%
Margin	15%	16%	24%	23%	25%	23%	24%
Other income	12	7	72	22	28	14	13
Interest	45	48	49	44	34	31	34
Depreciation	91	89	88	94	96	94	95
Profit before tax	58	77	330	211	289 +398%	234 +204%	259 −22%
Tax rate	27%	25%	24%	25%	25%	25%	26%
Net profit	42	57	252	158	216 +414%	175 +207%	192 −24%
EPS	0.79	1.06	4.67	2.93	4.00	3.24	3.55

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls